BZYR
BURZYNSKI RESEARCH INSTITUTE INCCompany Information
- Company Name
- BURZYNSKI RESEARCH INSTITUTE INC
- CIK
- CIK0000724445
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- BZYR: OTC
- Fiscal Year End
- February 28
- Owner Organization
- 03 Life Sciences
- SIC
- 2835
- SIC Description
- In Vitro & In Vivo Diagnostic Substances
- Ticker
- BZYR
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- —
- Institutional shares owned
- —
- Shares outstanding
- —
- Ownership
- —
Earnings Market Reaction
- Filing date
- 2026-01-13
- Price on filing date
- —
- 1-month reaction
- -10.53%
- 3-month reaction
- -34.21%
Balance Sheet
Values in millions ($)| Line item | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2025-02-28 | 2024-11-30 | 2024-08-31 | 2024-05-31 | 2024-02-29 | 2023-11-30 | 2023-08-31 | 2023-05-31 | 2023-02-28 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense Current | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | ||||||
| Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 130 | 130 | 130 | 129 | 129 | 129 | 128 | 128 | 128 | 127 | 127 | 127 | ||||||
| Retained Earnings Accumulated Deficit | -130 | -130 | -130 | -129 | -129 | -129 | -128 | -128 | -128 | -127 | -127 | -127 | ||||||
| Stockholders Equity | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Liabilities And Stockholders Equity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 131 | 131 | 131 | 131 | 131 | 131 | 131 | 131 | 131 | 131 | 131 | 131 | ||||||
| Shares Outstanding | 131 | 131 | 131 | 131 | 131 | 131 | 131 | 131 | 131 | 131 | 131 | 131 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBURZYNSKI RESEARCH INSTITUTE INC (BZYR) — SEC Financial Statements & Analysis
BURZYNSKI RESEARCH INSTITUTE INC (BZYR) is a in vitro & in vivo diagnostic substances company, incorporated in DE. BURZYNSKI RESEARCH INSTITUTE INC trades on OTC as: BZYR. BURZYNSKI RESEARCH INSTITUTE INC (BZYR)'s most recent SEC filing is a Form 10-Q for the period ended 2025-11-30, filed with the SEC on 2026-01-13. Based on that filing, BURZYNSKI RESEARCH INSTITUTE INC carries a market cap of $5.78M, a P/E ratio of -4.36x, a P/B ratio of -85.88x, an enterprise value of $5.78M, and an EV/EBITDA multiple of -4.49x. On profitability, it posts a Return on Equity (ROE) of 2992.84% and a Return on Assets (ROA) of -89110.75%. Per share, it reports EPS of $-0.01, diluted EPS of $-0.01, free cash flow per share of $-0.00, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -3.32% year-over-year and EPS growth of -3.32% year-over-year. On the balance sheet, it maintains free cash flow of $-257.78K (TTM) and net debt of $-2.17K. Figures sourced from SEC EDGAR.
- Market Cap
- $5.78M
- P/E TTM
- -4.36x
- EPS TTM
- $-0.01
- P/B TTM
- -85.88x
- ROE TTM
- 2992.84%
- ROA TTM
- -89110.75%
- Free Cash Flow TTM
- $-257.78K
Data as of 2025-11-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BURZYNSKI RESEARCH INSTITUTE INC in?
BURZYNSKI RESEARCH INSTITUTE INC (BZYR) operates in the In Vitro & In Vivo Diagnostic Substances industry.
What exchange does BZYR trade on?
BURZYNSKI RESEARCH INSTITUTE INC (BZYR) trades on the OTC.
Where is BURZYNSKI RESEARCH INSTITUTE INC incorporated?
BURZYNSKI RESEARCH INSTITUTE INC is incorporated in DE.
When was BURZYNSKI RESEARCH INSTITUTE INC (BZYR)'s most recent SEC filing?
BURZYNSKI RESEARCH INSTITUTE INC (BZYR)'s most recent SEC filing is a Form 10-Q for the period ended 2025-11-30, filed with the SEC on 2026-01-13.
What is BZYR's market cap?
BURZYNSKI RESEARCH INSTITUTE INC (BZYR) has a market capitalization of $5.78M as of 2025-11-30.
What is BZYR's EPS (earnings per share)?
BURZYNSKI RESEARCH INSTITUTE INC (BZYR)'s trailing twelve month EPS is $-0.01 as of 2025-11-30.
What is BZYR's ROE (return on equity)?
BURZYNSKI RESEARCH INSTITUTE INC (BZYR)'s trailing twelve month Return on Equity (ROE) is 2992.84% as of 2025-11-30.
What is BZYR's ROA (return on assets)?
BURZYNSKI RESEARCH INSTITUTE INC (BZYR)'s trailing twelve month Return on Assets (ROA) is -89110.75% as of 2025-11-30.
What is BZYR's EV/EBITDA?
BURZYNSKI RESEARCH INSTITUTE INC (BZYR)'s trailing twelve month EV/EBITDA is -4.49x as of 2025-11-30.